Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...

Weekly Vaccination With Copaxone as a Potential Therapy for Dry Age-related Macular Degeneration

This study has suspended participant recruitment.
(Reviewing data)
Information provided by (Responsible Party):
The New York Eye & Ear Infirmary Identifier:
First received: October 9, 2007
Last updated: May 2, 2013
Last verified: May 2013
The purpose of the project is to investigate in eyes with dry AMD, the efficacy and safety as preventive therapy of the immunomodulatory substance named copaxone which had been proven as safe and effective agent for a neurodegenerative disease, in arresting the progression as well as the conversion of dry AMD to wet AMD. The hypothesis that the immunomodulatory agent copaxone proven for a neurodegenerative disease may work in the eye is revolutionary and may open a new avenue of preventive treatment for the disease which is the major cause of legal blindness in the industrial world

Condition Intervention Phase
Dry Age Related Macular Degeneration
Drug: Copaxone Injection
Phase 1

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double Blind (Participant, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: Weekly Vaccination With Copaxone as a Potential Therapy for Dry Age-related Macular Degeneration

Resource links provided by NLM:

Further study details as provided by The New York Eye & Ear Infirmary:

Primary Outcome Measures:
  • Total drusen area reduction [ Time Frame: 1 year ]

Enrollment: 15
Study Start Date: December 2007
Primary Completion Date: December 2012 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Active Comparator: Copaxone Drug: Copaxone Injection
Sham Comparator: Sham Drug: Copaxone Injection


Ages Eligible for Study:   50 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  1. Dry AMD in one or both eyes
  2. Age 50 or above of either gender
  3. Signed informed consent.

Exclusion Criteria:

  1. Known sensitivity to Mannitol or Copaxone.
  2. Skin disease or active infection of skin.
  3. Active fever or active treatment for infection.
  4. History of other uncontrolled systemic active disease.
  5. Premenopausal females not using reliable birth control.
  6. Sensitivity to fluorescein or iodine.
  7. Inability to comply with study procedures.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00541333

United States, New York
New York Eye and Ear Infirmary
New York, New York, United States
Sponsors and Collaborators
The New York Eye & Ear Infirmary
Principal Investigator: Richard B Rosen, MD New York Eye and Ear Infirmary
  More Information

Responsible Party: The New York Eye & Ear Infirmary Identifier: NCT00541333     History of Changes
Other Study ID Numbers: NYEE100907
Study First Received: October 9, 2007
Last Updated: May 2, 2013

Keywords provided by The New York Eye & Ear Infirmary:
Dry Age Related Macular Degeneration

Additional relevant MeSH terms:
Macular Degeneration
Retinal Degeneration
Retinal Diseases
Eye Diseases
Glatiramer Acetate
Adjuvants, Immunologic
Immunologic Factors
Physiological Effects of Drugs
Immunosuppressive Agents
Antirheumatic Agents processed this record on April 28, 2017